UNSPSC 51292303: Tropanserin

This classification denotes a serotonin antagonist with the molecular formula C17H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04B48I6VHR, chemically known as tropyl 3,5-dimethylbenzoate but generally known as tropanserin, which bears US NIH Compound Identifier 68600. European Medicines Agency schedules Tropanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11338MIG.

UNSPSC 51292303 Tropanserin is a Commodity code that maps poorly to the recent state and local procurement activity tagged under it. The three most recent opportunities show no solicitation for tropanserin itself — a dopamine agonist pharmaceutical — but rather for naloxone kits, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing channels, and direct-to-manufacturer prescription program capabilities. The code name does not align with the actual procurement scope, which spans emergency-response pharmaceuticals, generic pharmaceutical supply agreements, and pharmacy benefit program infrastructure rather than a single active pharmaceutical ingredient. State and local buyers using this code appear to be health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the issuing bodies in recent activity.

The geographic spread captures Florida, Texas, and Minnesota with multi-state reach through MMCAP's cooperative purchasing structure. Seminole County posted IFB 60459723LAS on June 30, 2026, with a July 26, 2023 deadline (note: date discrepancy in source), to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and fixed-fee pricing on an initial two-year term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving self-insured state agencies and employee health plans. MMCAP released RFP S1070000015802 on January 20, 2026, with a March 26, 2026 deadline, to establish multi-award contracts for generic and OTC pharmaceuticals distributed through three authorized wholesalers, effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and pricing format flexibility. The code shows minimal recent activity; the mismatch between the tropanserin commodity name and actual procurement scope suggests misclassification or administrative tagging error.